L3VLUP
ProSign in

PCRX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PCRXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PCRX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterPCRXJNJ
Q3 20205 holders, $344m30 holders, $26.2bn
Q4 20205 holders, $335m32 holders, $26.6bn
Q1 20214 holders, $313m31 holders, $25.3bn
Q2 20216 holders, $303m37 holders, $25.6bn
Q3 20216 holders, $251m40 holders, $24.1bn
Q4 20216 holders, $269m33 holders, $25.2bn
Q1 20226 holders, $332m35 holders, $28.2bn
Q2 20225 holders, $239m33 holders, $26.9bn
Q3 20225 holders, $206m36 holders, $25.4bn
Q4 20225 holders, $144m35 holders, $27.6bn
Q1 20236 holders, $174m42 holders, $24.5bn
Q2 20238 holders, $174m38 holders, $25.0bn
Q3 20235 holders, $111m37 holders, $18.9bn
Q4 20235 holders, $102m31 holders, $19.0bn
Q1 20243 holders, $108m32 holders, $19.7bn
Q2 20244 holders, $113m35 holders, $20.4bn
Q3 20244 holders, $41m28 holders, $22.3bn
Q4 20244 holders, $68m37 holders, $20.4bn
Q1 20257 holders, $178m32 holders, $20.5bn
Q2 20255 holders, $117m31 holders, $18.4bn
Q3 20254 holders, $109m32 holders, $23.7bn
Q4 20255 holders, $57m29 holders, $27.8bn
Q1 20263 holders, $45m34 holders, $35.6bn
Q2 20263 holders, $49m33 holders, $39.1bn
PCRX

Pacira Biosciences Inc

Holders
4
Reported value
$113m
Buyers
3
Sellers
1

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
35
Reported value
$20.4bn
Buyers
24
Sellers
8

Breadth +16 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PCRX (2)

Baillie Gifford & Co, Winton Group Ltd

Only JNJ (33)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC, and 8 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →